Zacks: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Given $10.00 Average Target Price by Analysts
Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) have received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price target of $10.00 for the company, according to Zacks. Zacks has also given Adamis Pharmaceuticals Corporation an industry rank of 167 out of 265 based on the ratings given to related companies.
Several research analysts have commented on the stock. Maxim Group restated a “buy” rating and set a $10.00 price objective on shares of Adamis Pharmaceuticals Corporation in a research report on Monday, June 12th. Zacks Investment Research downgraded shares of Adamis Pharmaceuticals Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, March 21st. Finally, ValuEngine upgraded shares of Adamis Pharmaceuticals Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 6th.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) traded down 0.93% during midday trading on Monday, reaching $5.30. The company had a trading volume of 577,992 shares. Adamis Pharmaceuticals Corporation has a 12 month low of $2.40 and a 12 month high of $6.45. The stock’s market cap is $146.08 million. The firm has a 50-day moving average of $4.36 and a 200-day moving average of $3.84.
An institutional investor recently raised its position in Adamis Pharmaceuticals Corporation stock. Sterling Global Strategies LLC boosted its stake in shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) by 6.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,600 shares of the specialty pharmaceutical company’s stock after buying an additional 2,600 shares during the period. Adamis Pharmaceuticals Corporation comprises approximately 0.9% of Sterling Global Strategies LLC’s investment portfolio, making the stock its 27th largest position. Sterling Global Strategies LLC’s holdings in Adamis Pharmaceuticals Corporation were worth $181,000 as of its most recent SEC filing. 11.29% of the stock is currently owned by institutional investors and hedge funds.
Adamis Pharmaceuticals Corporation Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.